INT285482

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 3.02
Pain Relevance 1.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Il22) extracellular region (Il22)
Anatomy Link Frequency
Th17 cell 1
Il22 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 101 100.00 Very High Very High Very High
Etanercept 25 99.98 Very High Very High Very High
cytokine 104 98.20 Very High Very High Very High
psoriasis 99 97.64 Very High Very High Very High
antagonist 5 97.30 Very High Very High Very High
Inflammatory mediators 7 91.76 High High
Crohn's disease 52 84.40 Quite High
chemokine 21 75.20 Quite High
cINOD 3 25.92 Quite Low
rheumatoid arthritis 88 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
INFLAMMATION 101 100.00 Very High Very High Very High
Acanthosis 5 99.16 Very High Very High Very High
Psoriasis 117 97.64 Very High Very High Very High
Pressure And Volume Under Development 4 89.32 High High
Disease 153 84.40 Quite High
Inflammatory Bowel Disease 59 74.44 Quite High
Targeted Disruption 7 70.48 Quite High
Skin Diseases 5 61.64 Quite High
Autoimmune Disease 37 50.00 Quite Low
Dermatitis 1 38.36 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The observed increase in expression levels of IL17A, IL17F, IL22 and IL26 and the downstream proinflammatory cytokines IL6 and IL1?
Negative_regulation (levels) of IL22 associated with cytokine
1) Confidence 0.30 Published 2010 Journal BMC Immunol Section Body Doc Link PMC3016394 Disease Relevance 0.89 Pain Relevance 0.44
antagonist therapy may be similar to the mechanism of ustekinumab by down-regulating pro-inflammatory pathways in lesional skin.25,26 Etanercept reduced the inflammatory dendritic cell products that drive Th17 cell proliferation (IL-23), as well as Th17 cell products and downstream effector molecules (IL-17, IL-22, CCL 20, and beta-defensin 4).
Negative_regulation (reduced) of IL-22 in Th17 cell associated with inflammation, antagonist and etanercept
2) Confidence 0.10 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857612 Disease Relevance 1.01 Pain Relevance 0.57
Together, these findings argue for a particular role of IL-22 mediating epidermal acanthosis and tissue inflammation in psoriasis after induction by IL-23.
Negative_regulation (role) of IL-22 associated with psoriasis, inflammation and acanthosis
3) Confidence 0.09 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2768824 Disease Relevance 1.12 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox